Following the successful launch in 2024, 2025 marked a year of expansion and measurable progress for WIND-PSC. The study continues to build the largest global prospective observational cohort of adult PSC patients, with a focus on understanding disease progression, biomarkers and patient symptoms that will support the development of new treatment for PSC.
Over 440 participants enrolled as of November 2025, a clear sign of growing community support. Additionally, 120 participants have achieved the 1-year follow-up milestone with a very low drop-out rate, demonstrating the commitment of the participants and the sites to this project. We are targeting to complete enrollment by late 2026 to early 2027.
Fifteen active WIND-PSC sites across the U.S., Canada, Germany, Italy, and New Zealand, with 4 additional sites in start-up phase and slated to begin enrolling early in 2026.
| SITE | PI | ||
|---|---|---|---|
| Aucland Hospitals Research Center | Hannah Giles | ||
| Beth-Israel Deaconess | Viles Patwardhan | ||
| California Pacific Medical Center | Kidist K. Yimam | ||
| Erasmus University | Adriaan Van Der Meer | ||
| Hamburg, Germany | Christoph Schramm | ||
| Indiana University | Craig Lammert | ||
| Mass. General Hospital/Harvard | Daniel Pratt | ||
| Mayo Clinic Rochester | John Eaton | ||
| Montreal | Julian Hercun | ||
| Oxford | Emma Culver | ||
| UC Davis | Chris Bowlus | ||
| UC San Francisco | Michael Li | ||
| University Health Network | Gideon Hirschfield | ||
| University of Alberta | Also Montana-Loza | ||
| University of Miami | Cynthia Levy | ||
| University of Milan | Laura Cristoferi | ||
| UT Southwestern | Marlyn Mayo | ||
| VCU | Obi Aseem | ||
| Yale | Marina G. Silveira |
- WIND-PSC engaged in strategic discussions with both the FDA and EMA, exploring how the cohort’s real-world data could be used to support future clinical trials and serve as a potential external control arm for PSC drug development.
- Initial data from the patients enrolled to date were presented in multiple forums at major international medical meetings, including the American Association for the Study of Liver Disease (AASLD) and European International Liver Congress (EASL ILC), reinforcing the project’s leadership in defining PSC natural history as well as establishing a roadmap for other rare diseases.
- As part of the continued growth of the project, we have welcomed a new Director of Clinical Research, Zuha Jeddy. She is a CDC-trained epidemiologist who has led large population-based studies, including COVID-19 research, and is also a certified project manager. She brings a wealth of experience, strong organizational skills, and dynamic leadership that will strengthen WIND and our other key research initiatives.
To find participating locations and to learn more about the study, visit: ClinicalTrials.gov study record: NCT06297993.
(Please note that due to the study’s protocol, participants must reside near and receive care at one of the participating study sites. If you are local to one of these sites, we encourage you to reach out to them directly to learn more about the enrollment process. As the study sponsor, PSC Partners is not involved in direct enrollment and cannot have access to participant information including knowing who is participating in the study).
Posted July 2025
